Michel Vounatsos MBA

Michel Vounatsos is Chief Executive Officer at Biogen and has served in this position and as a member of the Board of Directors since January 2017. Prior to that, from April 2016 until his appointment as our Chief Executive Officer, he served as our Executive Vice President, Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck & Co., Inc., a pharmaceutical company, where he most recently served as President, Primary Care Business Line, and Merck Customer Centricity. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health, and biosimilars groups and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payers and retailers, and the world’s largest governments.

Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company. Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.

Mr. Vounatsos is also a member of the Board of Directors of PerkinElmer, Inc., a global science technology and life science research company, and currently serves as the Chairman of the Supervisory Board of the Electrophysiology and Heart Modeling Institute at the University of Bordeaux, on the Board of Directors of N-Lorem Ultra-Rare Disease Foundation, on the Board of Directors of Early Detection of Neurodegenerative Diseases, on the advisory board of Tsinghua University School of Pharmaceutical Sciences, on the Supervisory Board of Liryc, and as a member of the MIT Presidential CEO Advisory Board.